nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3A—penis—skin cancer	0.0465	0.145	CbGeAlD
Lithium—GRIA3—nerve—skin cancer	0.0284	0.0882	CbGeAlD
Lithium—GSK3B—nerve—skin cancer	0.0246	0.0764	CbGeAlD
Lithium—IMPA2—hair follicle—skin cancer	0.021	0.0652	CbGeAlD
Lithium—GSK3B—hair follicle—skin cancer	0.0206	0.0639	CbGeAlD
Lithium—GSK3A—hair follicle—skin cancer	0.0179	0.0556	CbGeAlD
Lithium—Psoriasis flare-up—Imiquimod—skin cancer	0.017	0.0656	CcSEcCtD
Lithium—IMPA2—nipple—skin cancer	0.0142	0.0442	CbGeAlD
Lithium—GSK3A—nipple—skin cancer	0.0121	0.0377	CbGeAlD
Lithium—GSK3B—connective tissue—skin cancer	0.00989	0.0307	CbGeAlD
Lithium—IMPA1—lymphoid tissue—skin cancer	0.00982	0.0305	CbGeAlD
Lithium—IMPA1—female reproductive system—skin cancer	0.00947	0.0294	CbGeAlD
Lithium—GSK3B—epithelium—skin cancer	0.00939	0.0292	CbGeAlD
Lithium—IMPA2—skin of body—skin cancer	0.0091	0.0283	CbGeAlD
Lithium—GSK3A—connective tissue—skin cancer	0.0086	0.0267	CbGeAlD
Lithium—IMPA2—mammalian vulva—skin cancer	0.0083	0.0258	CbGeAlD
Lithium—IMPA1—head—skin cancer	0.00791	0.0246	CbGeAlD
Lithium—GSK3B—lymphoid tissue—skin cancer	0.00723	0.0225	CbGeAlD
Lithium—IMPA2—female reproductive system—skin cancer	0.00711	0.0221	CbGeAlD
Lithium—GSK3A—mammalian vulva—skin cancer	0.00708	0.022	CbGeAlD
Lithium—GSK3B—female reproductive system—skin cancer	0.00697	0.0217	CbGeAlD
Lithium—GRIA3—head—skin cancer	0.00673	0.0209	CbGeAlD
Lithium—GSK3A—female reproductive system—skin cancer	0.00606	0.0189	CbGeAlD
Lithium—Electrocardiogram change—Fluorouracil—skin cancer	0.00601	0.0231	CcSEcCtD
Lithium—GSK3B—head—skin cancer	0.00583	0.0181	CbGeAlD
Lithium—Folliculitis—Vemurafenib—skin cancer	0.0058	0.0223	CcSEcCtD
Lithium—GSK3A—head—skin cancer	0.00507	0.0157	CbGeAlD
Lithium—Folliculitis—Imiquimod—skin cancer	0.00495	0.0191	CcSEcCtD
Lithium—Psoriasis—Imiquimod—skin cancer	0.00495	0.0191	CcSEcCtD
Lithium—IMPA2—lymph node—skin cancer	0.00416	0.0129	CbGeAlD
Lithium—GSK3B—lymph node—skin cancer	0.00408	0.0127	CbGeAlD
Lithium—Skin ulcer—Imiquimod—skin cancer	0.00399	0.0154	CcSEcCtD
Lithium—Dehydration—Vismodegib—skin cancer	0.00398	0.0153	CcSEcCtD
Lithium—Slurred speech—Fluorouracil—skin cancer	0.00384	0.0148	CcSEcCtD
Lithium—GSK3A—lymph node—skin cancer	0.00355	0.011	CbGeAlD
Lithium—Weight decreased—Vismodegib—skin cancer	0.00335	0.0129	CcSEcCtD
Lithium—Folliculitis—Dactinomycin—skin cancer	0.00328	0.0126	CcSEcCtD
Lithium—Chest tightness—Docetaxel—skin cancer	0.00264	0.0102	CcSEcCtD
Lithium—Alopecia—Vismodegib—skin cancer	0.00262	0.0101	CcSEcCtD
Lithium—Swelling—Imiquimod—skin cancer	0.00256	0.00985	CcSEcCtD
Lithium—Dysgeusia—Vismodegib—skin cancer	0.00253	0.00973	CcSEcCtD
Lithium—Extrapyramidal disorder—Temozolomide—skin cancer	0.00247	0.00953	CcSEcCtD
Lithium—Scotoma—Temozolomide—skin cancer	0.00245	0.00945	CcSEcCtD
Lithium—Dry skin—Vemurafenib—skin cancer	0.00243	0.00934	CcSEcCtD
Lithium—Nystagmus—Fluorouracil—skin cancer	0.0024	0.00926	CcSEcCtD
Lithium—Memory impairment—Temozolomide—skin cancer	0.00237	0.00914	CcSEcCtD
Lithium—Lethargy—Imiquimod—skin cancer	0.0023	0.00887	CcSEcCtD
Lithium—Arthralgia—Vismodegib—skin cancer	0.0022	0.00846	CcSEcCtD
Lithium—Weight decreased—Vemurafenib—skin cancer	0.00207	0.00797	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vismodegib—skin cancer	0.00192	0.00739	CcSEcCtD
Lithium—Coordination abnormal—Temozolomide—skin cancer	0.0019	0.00731	CcSEcCtD
Lithium—Dyspepsia—Vismodegib—skin cancer	0.00185	0.00714	CcSEcCtD
Lithium—Decreased appetite—Vismodegib—skin cancer	0.00183	0.00705	CcSEcCtD
Lithium—Leukocytosis—Fluorouracil—skin cancer	0.00183	0.00704	CcSEcCtD
Lithium—Fatigue—Vismodegib—skin cancer	0.00182	0.00699	CcSEcCtD
Lithium—Dysarthria—Fluorouracil—skin cancer	0.00182	0.00699	CcSEcCtD
Lithium—Urinary incontinence—Temozolomide—skin cancer	0.0018	0.00693	CcSEcCtD
Lithium—Depressed level of consciousness—Temozolomide—skin cancer	0.0018	0.00693	CcSEcCtD
Lithium—Erectile dysfunction—Imiquimod—skin cancer	0.0018	0.00692	CcSEcCtD
Lithium—Gastrointestinal pain—Vismodegib—skin cancer	0.00172	0.00663	CcSEcCtD
Lithium—Abdominal pain—Vismodegib—skin cancer	0.00166	0.00641	CcSEcCtD
Lithium—Scotoma—Docetaxel—skin cancer	0.00163	0.00628	CcSEcCtD
Lithium—Alopecia—Vemurafenib—skin cancer	0.00162	0.00623	CcSEcCtD
Lithium—Coma—Fluorouracil—skin cancer	0.00157	0.00604	CcSEcCtD
Lithium—Dysgeusia—Vemurafenib—skin cancer	0.00156	0.00601	CcSEcCtD
Lithium—Lethargy—Dactinomycin—skin cancer	0.00153	0.00588	CcSEcCtD
Lithium—Asthenia—Vismodegib—skin cancer	0.00151	0.00582	CcSEcCtD
Lithium—Tinnitus—Imiquimod—skin cancer	0.00146	0.00561	CcSEcCtD
Lithium—Diarrhoea—Vismodegib—skin cancer	0.00144	0.00555	CcSEcCtD
Lithium—Thirst—Temozolomide—skin cancer	0.00142	0.00547	CcSEcCtD
Lithium—Swelling—Fluorouracil—skin cancer	0.00141	0.00544	CcSEcCtD
Lithium—Chest discomfort—Docetaxel—skin cancer	0.0014	0.00539	CcSEcCtD
Lithium—Arrhythmia—Imiquimod—skin cancer	0.00139	0.00537	CcSEcCtD
Lithium—Alopecia—Imiquimod—skin cancer	0.00138	0.00531	CcSEcCtD
Lithium—Arthralgia—Vemurafenib—skin cancer	0.00136	0.00523	CcSEcCtD
Lithium—Oliguria—Docetaxel—skin cancer	0.00134	0.00518	CcSEcCtD
Lithium—Vomiting—Vismodegib—skin cancer	0.00134	0.00516	CcSEcCtD
Lithium—Rash—Vismodegib—skin cancer	0.00133	0.00511	CcSEcCtD
Lithium—Dermatitis—Vismodegib—skin cancer	0.00133	0.00511	CcSEcCtD
Lithium—Ataxia—Temozolomide—skin cancer	0.00127	0.0049	CcSEcCtD
Lithium—Lethargy—Fluorouracil—skin cancer	0.00127	0.0049	CcSEcCtD
Lithium—Dehydration—Temozolomide—skin cancer	0.00126	0.00484	CcSEcCtD
Lithium—Weight decreased—Bleomycin—skin cancer	0.00125	0.00483	CcSEcCtD
Lithium—Nausea—Vismodegib—skin cancer	0.00125	0.00482	CcSEcCtD
Lithium—Agitation—Imiquimod—skin cancer	0.00125	0.00481	CcSEcCtD
Lithium—Angioedema—Imiquimod—skin cancer	0.00124	0.00478	CcSEcCtD
Lithium—Dry skin—Temozolomide—skin cancer	0.00124	0.00477	CcSEcCtD
Lithium—Syncope—Imiquimod—skin cancer	0.00122	0.00469	CcSEcCtD
Lithium—Hypotension—Vemurafenib—skin cancer	0.00122	0.00468	CcSEcCtD
Lithium—Loss of consciousness—Imiquimod—skin cancer	0.00119	0.0046	CcSEcCtD
Lithium—Muscular weakness—Temozolomide—skin cancer	0.00119	0.00459	CcSEcCtD
Lithium—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00119	0.00456	CcSEcCtD
Lithium—Convulsion—Imiquimod—skin cancer	0.00118	0.00454	CcSEcCtD
Lithium—Ataxia—Fluorouracil—skin cancer	0.00117	0.00451	CcSEcCtD
Lithium—Arthralgia—Imiquimod—skin cancer	0.00116	0.00446	CcSEcCtD
Lithium—Discomfort—Imiquimod—skin cancer	0.00114	0.0044	CcSEcCtD
Lithium—Dry skin—Fluorouracil—skin cancer	0.00114	0.0044	CcSEcCtD
Lithium—Dry mouth—Imiquimod—skin cancer	0.00113	0.00436	CcSEcCtD
Lithium—Decreased appetite—Vemurafenib—skin cancer	0.00113	0.00435	CcSEcCtD
Lithium—Fatigue—Vemurafenib—skin cancer	0.00112	0.00432	CcSEcCtD
Lithium—Oedema—Imiquimod—skin cancer	0.00111	0.00427	CcSEcCtD
Lithium—Muscular weakness—Fluorouracil—skin cancer	0.0011	0.00423	CcSEcCtD
Lithium—Shock—Imiquimod—skin cancer	0.00109	0.0042	CcSEcCtD
Lithium—Erectile dysfunction—Temozolomide—skin cancer	0.00108	0.00415	CcSEcCtD
Lithium—Weight increased—Temozolomide—skin cancer	0.00106	0.0041	CcSEcCtD
Lithium—Weight decreased—Temozolomide—skin cancer	0.00106	0.00407	CcSEcCtD
Lithium—Anorexia—Imiquimod—skin cancer	0.00106	0.00407	CcSEcCtD
Lithium—Hyperglycaemia—Temozolomide—skin cancer	0.00105	0.00406	CcSEcCtD
Lithium—Body temperature increased—Vemurafenib—skin cancer	0.00103	0.00396	CcSEcCtD
Lithium—Swelling—Docetaxel—skin cancer	0.00102	0.00393	CcSEcCtD
Lithium—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00101	0.00389	CcSEcCtD
Lithium—Somnolence—Imiquimod—skin cancer	0.000986	0.0038	CcSEcCtD
Lithium—Alopecia—Bleomycin—skin cancer	0.00098	0.00378	CcSEcCtD
Lithium—Dyspepsia—Imiquimod—skin cancer	0.000977	0.00376	CcSEcCtD
Lithium—Decreased appetite—Imiquimod—skin cancer	0.000964	0.00371	CcSEcCtD
Lithium—Fatigue—Imiquimod—skin cancer	0.000956	0.00368	CcSEcCtD
Lithium—Asthenia—Vemurafenib—skin cancer	0.000933	0.00359	CcSEcCtD
Lithium—Hallucination—Temozolomide—skin cancer	0.000931	0.00359	CcSEcCtD
Lithium—Lethargy—Docetaxel—skin cancer	0.000918	0.00354	CcSEcCtD
Lithium—Alopecia—Dactinomycin—skin cancer	0.000914	0.00352	CcSEcCtD
Lithium—Feeling abnormal—Imiquimod—skin cancer	0.000914	0.00352	CcSEcCtD
Lithium—Gastrointestinal pain—Imiquimod—skin cancer	0.000907	0.00349	CcSEcCtD
Lithium—Diarrhoea—Vemurafenib—skin cancer	0.00089	0.00343	CcSEcCtD
Lithium—Body temperature increased—Imiquimod—skin cancer	0.000877	0.00338	CcSEcCtD
Lithium—Abdominal pain—Imiquimod—skin cancer	0.000877	0.00338	CcSEcCtD
Lithium—Tinnitus—Temozolomide—skin cancer	0.000872	0.00336	CcSEcCtD
Lithium—Dizziness—Vemurafenib—skin cancer	0.00086	0.00331	CcSEcCtD
Lithium—Ataxia—Docetaxel—skin cancer	0.000846	0.00326	CcSEcCtD
Lithium—Dehydration—Docetaxel—skin cancer	0.000837	0.00322	CcSEcCtD
Lithium—Vomiting—Vemurafenib—skin cancer	0.000827	0.00319	CcSEcCtD
Lithium—Alopecia—Temozolomide—skin cancer	0.000827	0.00318	CcSEcCtD
Lithium—Dry skin—Docetaxel—skin cancer	0.000824	0.00318	CcSEcCtD
Lithium—Rash—Vemurafenib—skin cancer	0.00082	0.00316	CcSEcCtD
Lithium—Dermatitis—Vemurafenib—skin cancer	0.000819	0.00316	CcSEcCtD
Lithium—Headache—Vemurafenib—skin cancer	0.000815	0.00314	CcSEcCtD
Lithium—Discomfort—Bleomycin—skin cancer	0.000812	0.00313	CcSEcCtD
Lithium—Dysgeusia—Temozolomide—skin cancer	0.000798	0.00307	CcSEcCtD
Lithium—Asthenia—Imiquimod—skin cancer	0.000796	0.00307	CcSEcCtD
Lithium—Confusional state—Bleomycin—skin cancer	0.000795	0.00306	CcSEcCtD
Lithium—Oedema—Bleomycin—skin cancer	0.000788	0.00304	CcSEcCtD
Lithium—Nausea—Vemurafenib—skin cancer	0.000773	0.00298	CcSEcCtD
Lithium—Arrhythmia—Fluorouracil—skin cancer	0.00077	0.00297	CcSEcCtD
Lithium—Vision blurred—Temozolomide—skin cancer	0.000768	0.00296	CcSEcCtD
Lithium—Tremor—Temozolomide—skin cancer	0.000763	0.00294	CcSEcCtD
Lithium—Alopecia—Fluorouracil—skin cancer	0.000762	0.00293	CcSEcCtD
Lithium—Diarrhoea—Imiquimod—skin cancer	0.000759	0.00292	CcSEcCtD
Lithium—Discomfort—Dactinomycin—skin cancer	0.000758	0.00292	CcSEcCtD
Lithium—Anorexia—Bleomycin—skin cancer	0.000751	0.00289	CcSEcCtD
Lithium—Agitation—Temozolomide—skin cancer	0.000749	0.00288	CcSEcCtD
Lithium—Angioedema—Temozolomide—skin cancer	0.000744	0.00287	CcSEcCtD
Lithium—Hypotension—Bleomycin—skin cancer	0.000736	0.00284	CcSEcCtD
Lithium—Oedema—Dactinomycin—skin cancer	0.000735	0.00283	CcSEcCtD
Lithium—Dizziness—Imiquimod—skin cancer	0.000734	0.00283	CcSEcCtD
Lithium—Vertigo—Temozolomide—skin cancer	0.000732	0.00282	CcSEcCtD
Lithium—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000718	0.00277	CcSEcCtD
Lithium—Weight increased—Docetaxel—skin cancer	0.000708	0.00272	CcSEcCtD
Lithium—Vision blurred—Fluorouracil—skin cancer	0.000707	0.00272	CcSEcCtD
Lithium—Convulsion—Temozolomide—skin cancer	0.000706	0.00272	CcSEcCtD
Lithium—Vomiting—Imiquimod—skin cancer	0.000705	0.00272	CcSEcCtD
Lithium—Weight decreased—Docetaxel—skin cancer	0.000703	0.00271	CcSEcCtD
Lithium—Anorexia—Dactinomycin—skin cancer	0.000701	0.0027	CcSEcCtD
Lithium—Rash—Imiquimod—skin cancer	0.000699	0.00269	CcSEcCtD
Lithium—Dermatitis—Imiquimod—skin cancer	0.000699	0.00269	CcSEcCtD
Lithium—Headache—Imiquimod—skin cancer	0.000695	0.00268	CcSEcCtD
Lithium—Arthralgia—Temozolomide—skin cancer	0.000693	0.00267	CcSEcCtD
Lithium—Discomfort—Temozolomide—skin cancer	0.000685	0.00264	CcSEcCtD
Lithium—Decreased appetite—Bleomycin—skin cancer	0.000685	0.00264	CcSEcCtD
Lithium—Dry mouth—Temozolomide—skin cancer	0.000678	0.00261	CcSEcCtD
Lithium—Confusional state—Temozolomide—skin cancer	0.00067	0.00258	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.00067	0.00258	CcSEcCtD
Lithium—Oedema—Temozolomide—skin cancer	0.000665	0.00256	CcSEcCtD
Lithium—Nausea—Imiquimod—skin cancer	0.000659	0.00254	CcSEcCtD
Lithium—Convulsion—Fluorouracil—skin cancer	0.00065	0.0025	CcSEcCtD
Lithium—Feeling abnormal—Bleomycin—skin cancer	0.000649	0.0025	CcSEcCtD
Lithium—Decreased appetite—Dactinomycin—skin cancer	0.000639	0.00246	CcSEcCtD
Lithium—Fatigue—Dactinomycin—skin cancer	0.000634	0.00244	CcSEcCtD
Lithium—Anorexia—Temozolomide—skin cancer	0.000634	0.00244	CcSEcCtD
Lithium—Discomfort—Fluorouracil—skin cancer	0.000631	0.00243	CcSEcCtD
Lithium—Body temperature increased—Bleomycin—skin cancer	0.000623	0.0024	CcSEcCtD
Lithium—Confusional state—Fluorouracil—skin cancer	0.000618	0.00238	CcSEcCtD
Lithium—Oedema—Fluorouracil—skin cancer	0.000613	0.00236	CcSEcCtD
Lithium—Feeling abnormal—Dactinomycin—skin cancer	0.000606	0.00233	CcSEcCtD
Lithium—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000606	0.00233	CcSEcCtD
Lithium—Gastrointestinal pain—Dactinomycin—skin cancer	0.000601	0.00231	CcSEcCtD
Lithium—Somnolence—Temozolomide—skin cancer	0.000591	0.00228	CcSEcCtD
Lithium—Dyspepsia—Temozolomide—skin cancer	0.000585	0.00225	CcSEcCtD
Lithium—Anorexia—Fluorouracil—skin cancer	0.000584	0.00225	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—skin cancer	0.000581	0.00224	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—skin cancer	0.000581	0.00224	CcSEcCtD
Lithium—Decreased appetite—Temozolomide—skin cancer	0.000578	0.00223	CcSEcCtD
Lithium—Fatigue—Temozolomide—skin cancer	0.000573	0.00221	CcSEcCtD
Lithium—Hypotension—Fluorouracil—skin cancer	0.000572	0.0022	CcSEcCtD
Lithium—Asthenia—Bleomycin—skin cancer	0.000565	0.00218	CcSEcCtD
Lithium—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000558	0.00215	CcSEcCtD
Lithium—Arrhythmia—Docetaxel—skin cancer	0.000556	0.00214	CcSEcCtD
Lithium—Alopecia—Docetaxel—skin cancer	0.00055	0.00212	CcSEcCtD
Lithium—Feeling abnormal—Temozolomide—skin cancer	0.000548	0.00211	CcSEcCtD
Lithium—Somnolence—Fluorouracil—skin cancer	0.000545	0.0021	CcSEcCtD
Lithium—Gastrointestinal pain—Temozolomide—skin cancer	0.000544	0.00209	CcSEcCtD
Lithium—Dyspepsia—Fluorouracil—skin cancer	0.000539	0.00208	CcSEcCtD
Lithium—Decreased appetite—Fluorouracil—skin cancer	0.000532	0.00205	CcSEcCtD
Lithium—Dysgeusia—Docetaxel—skin cancer	0.00053	0.00204	CcSEcCtD
Lithium—Asthenia—Dactinomycin—skin cancer	0.000527	0.00203	CcSEcCtD
Lithium—Abdominal pain—Temozolomide—skin cancer	0.000526	0.00202	CcSEcCtD
Lithium—Body temperature increased—Temozolomide—skin cancer	0.000526	0.00202	CcSEcCtD
Lithium—Feeling abnormal—Fluorouracil—skin cancer	0.000505	0.00194	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—skin cancer	0.000503	0.00194	CcSEcCtD
Lithium—Vomiting—Bleomycin—skin cancer	0.000501	0.00193	CcSEcCtD
Lithium—Rash—Bleomycin—skin cancer	0.000497	0.00191	CcSEcCtD
Lithium—Dermatitis—Bleomycin—skin cancer	0.000496	0.00191	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	0.000493	0.00118	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—KRAS—skin cancer	0.000488	0.00117	CbGpPWpGaD
Lithium—Syncope—Docetaxel—skin cancer	0.000486	0.00187	CcSEcCtD
Lithium—Body temperature increased—Fluorouracil—skin cancer	0.000484	0.00186	CcSEcCtD
Lithium—Asthenia—Temozolomide—skin cancer	0.000477	0.00184	CcSEcCtD
Lithium—Loss of consciousness—Docetaxel—skin cancer	0.000476	0.00183	CcSEcCtD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	0.000473	0.00113	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—NRAS—skin cancer	0.000473	0.00113	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—NRAS—skin cancer	0.000473	0.00113	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ERCC2—skin cancer	0.000471	0.00113	CbGpPWpGaD
Lithium—Convulsion—Docetaxel—skin cancer	0.000469	0.00181	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—NRAS—skin cancer	0.000469	0.00112	CbGpPWpGaD
Lithium—Nausea—Bleomycin—skin cancer	0.000468	0.0018	CcSEcCtD
Lithium—GSK3A—Downstream signaling of activated FGFR—KRAS—skin cancer	0.000467	0.00112	CbGpPWpGaD
Lithium—Vomiting—Dactinomycin—skin cancer	0.000467	0.0018	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000465	0.00111	CbGpPWpGaD
Lithium—Rash—Dactinomycin—skin cancer	0.000463	0.00178	CcSEcCtD
Lithium—GSK3A—Signaling by PDGF—NRAS—skin cancer	0.000463	0.00111	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—KRAS—skin cancer	0.000462	0.0011	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR7—skin cancer	0.000462	0.0011	CbGpPWpGaD
Lithium—Arthralgia—Docetaxel—skin cancer	0.000461	0.00178	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB4—KRAS—skin cancer	0.00046	0.0011	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDK4—skin cancer	0.000457	0.00109	CbGpPWpGaD
Lithium—Diarrhoea—Temozolomide—skin cancer	0.000455	0.00175	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL6—skin cancer	0.000453	0.00108	CbGpPWpGaD
Lithium—Dry mouth—Docetaxel—skin cancer	0.000451	0.00174	CcSEcCtD
Lithium—Confusional state—Docetaxel—skin cancer	0.000446	0.00172	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—KRAS—skin cancer	0.000443	0.00106	CbGpPWpGaD
Lithium—Oedema—Docetaxel—skin cancer	0.000442	0.0017	CcSEcCtD
Lithium—GSK3B—Signaling by Wnt—TERT—skin cancer	0.000441	0.00105	CbGpPWpGaD
Lithium—Dizziness—Temozolomide—skin cancer	0.00044	0.00169	CcSEcCtD
Lithium—GSK3A—Downstream signal transduction—KRAS—skin cancer	0.000439	0.00105	CbGpPWpGaD
Lithium—GRIA3—Transmission across Chemical Synapses—HRAS—skin cancer	0.000438	0.00105	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—NRAS—skin cancer	0.000438	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—KRAS—skin cancer	0.000437	0.00104	CbGpPWpGaD
Lithium—Nausea—Dactinomycin—skin cancer	0.000437	0.00168	CcSEcCtD
Lithium—Shock—Docetaxel—skin cancer	0.000435	0.00168	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB2—KRAS—skin cancer	0.000435	0.00104	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—KRAS—skin cancer	0.000433	0.00103	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	0.000427	0.00102	CbGpPWpGaD
Lithium—Vomiting—Temozolomide—skin cancer	0.000423	0.00163	CcSEcCtD
Lithium—Anorexia—Docetaxel—skin cancer	0.000421	0.00162	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—NRAS—skin cancer	0.000419	0.001	CbGpPWpGaD
Lithium—Rash—Temozolomide—skin cancer	0.000419	0.00161	CcSEcCtD
Lithium—Diarrhoea—Fluorouracil—skin cancer	0.000419	0.00161	CcSEcCtD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	0.000419	0.001	CbGpPWpGaD
Lithium—Dermatitis—Temozolomide—skin cancer	0.000419	0.00161	CcSEcCtD
Lithium—Headache—Temozolomide—skin cancer	0.000416	0.0016	CcSEcCtD
Lithium—GSK3B—Cell Cycle—TP53—skin cancer	0.000416	0.000993	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—skin cancer	0.000416	0.000993	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—HRAS—skin cancer	0.000415	0.000992	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—HRAS—skin cancer	0.000414	0.000988	CbGpPWpGaD
Lithium—Hypotension—Docetaxel—skin cancer	0.000413	0.00159	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—skin cancer	0.000411	0.000981	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—FOXO4—skin cancer	0.000409	0.000976	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—KRAS—skin cancer	0.000407	0.000973	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	0.000407	0.000973	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—KRAS—skin cancer	0.000407	0.000973	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—skin cancer	0.000406	0.00097	CbGpPWpGaD
Lithium—Dizziness—Fluorouracil—skin cancer	0.000405	0.00156	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—KRAS—skin cancer	0.000404	0.000964	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000403	0.00155	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—NRAS—skin cancer	0.000401	0.000958	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—KRAS—skin cancer	0.0004	0.000955	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—KRAS—skin cancer	0.000398	0.000951	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—IL6—skin cancer	0.000397	0.000949	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—HRAS—skin cancer	0.000397	0.000949	CbGpPWpGaD
Lithium—GSK3B—Disease—CSPG4—skin cancer	0.000397	0.000947	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—NRAS—skin cancer	0.000395	0.000943	CbGpPWpGaD
Lithium—Nausea—Temozolomide—skin cancer	0.000395	0.00152	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—skin cancer	0.000394	0.000941	CbGpPWpGaD
Lithium—Somnolence—Docetaxel—skin cancer	0.000393	0.00151	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—FOXO4—skin cancer	0.000392	0.000937	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—HRAS—skin cancer	0.000391	0.000934	CbGpPWpGaD
Lithium—Vomiting—Fluorouracil—skin cancer	0.000389	0.0015	CcSEcCtD
Lithium—Dyspepsia—Docetaxel—skin cancer	0.000389	0.0015	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—HRAS—skin cancer	0.000388	0.000928	CbGpPWpGaD
Lithium—Rash—Fluorouracil—skin cancer	0.000386	0.00149	CcSEcCtD
Lithium—Dermatitis—Fluorouracil—skin cancer	0.000386	0.00149	CcSEcCtD
Lithium—Decreased appetite—Docetaxel—skin cancer	0.000384	0.00148	CcSEcCtD
Lithium—Headache—Fluorouracil—skin cancer	0.000384	0.00148	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	0.000383	0.000915	CbGpPWpGaD
Lithium—Fatigue—Docetaxel—skin cancer	0.000381	0.00147	CcSEcCtD
Lithium—GSK3A—Downstream signaling of activated FGFR—IL6—skin cancer	0.00038	0.000908	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—BRAF—skin cancer	0.000379	0.000905	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—NRAS—skin cancer	0.000377	0.000901	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—HRAS—skin cancer	0.000377	0.0009	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—KRAS—skin cancer	0.000377	0.0009	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GLI2—skin cancer	0.000376	0.000897	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—NRAS—skin cancer	0.000375	0.000896	CbGpPWpGaD
Lithium—GSK3A—Insulin Signaling—HRAS—skin cancer	0.000375	0.000896	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—IL6—skin cancer	0.000374	0.000894	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—NRAS—skin cancer	0.000373	0.000892	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—HRAS—skin cancer	0.000373	0.000892	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL6—skin cancer	0.000372	0.000888	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—NRAS—skin cancer	0.000372	0.000887	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—HRAS—skin cancer	0.000372	0.000887	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—HRAS—skin cancer	0.00037	0.000883	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—HRAS—skin cancer	0.000368	0.000879	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTCH2—skin cancer	0.000366	0.000875	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	0.000366	0.000875	CbGpPWpGaD
Lithium—GSK3A—Disease—SHH—skin cancer	0.000365	0.000871	CbGpPWpGaD
Lithium—GSK3A—Disease—ENO2—skin cancer	0.000365	0.000871	CbGpPWpGaD
Lithium—Feeling abnormal—Docetaxel—skin cancer	0.000364	0.0014	CcSEcCtD
Lithium—Nausea—Fluorouracil—skin cancer	0.000364	0.0014	CcSEcCtD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	0.000363	0.000866	CbGpPWpGaD
Lithium—Gastrointestinal pain—Docetaxel—skin cancer	0.000362	0.00139	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—KRAS—skin cancer	0.000361	0.000862	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	0.000361	0.000861	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MC1R—skin cancer	0.000359	0.000856	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—IL6—skin cancer	0.000357	0.000853	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—IL6—skin cancer	0.000356	0.000849	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—IL6—skin cancer	0.000354	0.000845	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—GLI1—skin cancer	0.000353	0.000844	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—IL6—skin cancer	0.000352	0.000841	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	0.00035	0.000835	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—NRAS—skin cancer	0.00035	0.000835	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—NRAS—skin cancer	0.00035	0.000835	CbGpPWpGaD
Lithium—Body temperature increased—Docetaxel—skin cancer	0.000349	0.00135	CcSEcCtD
Lithium—Abdominal pain—Docetaxel—skin cancer	0.000349	0.00135	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—skin cancer	0.000349	0.000834	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—NRAS—skin cancer	0.000346	0.000827	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—HRAS—skin cancer	0.000346	0.000827	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—HRAS—skin cancer	0.000346	0.000827	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	0.000346	0.000827	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KRAS—skin cancer	0.000345	0.000825	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—NRAS—skin cancer	0.000343	0.00082	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—HRAS—skin cancer	0.000343	0.000819	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—NRAS—skin cancer	0.000342	0.000817	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	0.000341	0.000813	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—HRAS—skin cancer	0.00034	0.000812	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KRAS—skin cancer	0.00034	0.000812	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—HRAS—skin cancer	0.000339	0.000808	CbGpPWpGaD
Lithium—GRIA3—Neuronal System—HRAS—skin cancer	0.000336	0.000801	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SUFU—skin cancer	0.000335	0.0008	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	0.000331	0.000791	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—IL6—skin cancer	0.000331	0.000791	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—IL6—skin cancer	0.000331	0.000791	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—IL6—skin cancer	0.000328	0.000784	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—IL6—skin cancer	0.000325	0.000777	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KRAS—skin cancer	0.000325	0.000775	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—IL6—skin cancer	0.000324	0.000774	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—NRAS—skin cancer	0.000324	0.000773	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KRAS—skin cancer	0.000323	0.000771	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—NRAS—skin cancer	0.000322	0.00077	CbGpPWpGaD
Lithium—GSK3A—Immune System—FOXO4—skin cancer	0.000322	0.000769	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KRAS—skin cancer	0.000321	0.000768	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—HRAS—skin cancer	0.00032	0.000765	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KRAS—skin cancer	0.00032	0.000764	CbGpPWpGaD
Lithium—Asthenia—Docetaxel—skin cancer	0.000317	0.00122	CcSEcCtD
Lithium—IMPA2—Metabolism—PTGS2—skin cancer	0.000317	0.000757	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	0.000315	0.000753	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	0.00031	0.00074	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—HRAS—skin cancer	0.000307	0.000733	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	0.000307	0.000732	CbGpPWpGaD
Lithium—Diarrhoea—Docetaxel—skin cancer	0.000302	0.00116	CcSEcCtD
Lithium—GSK3B—BDNF signaling pathway—HRAS—skin cancer	0.000302	0.00072	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KRAS—skin cancer	0.000301	0.000719	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	0.000301	0.000719	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KRAS—skin cancer	0.000301	0.000719	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KRAS—skin cancer	0.000298	0.000712	CbGpPWpGaD
Lithium—GSK3A—Disease—FOXO4—skin cancer	0.000297	0.00071	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KRAS—skin cancer	0.000296	0.000706	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KRAS—skin cancer	0.000294	0.000703	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—IL6—skin cancer	0.000294	0.000701	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—HRAS—skin cancer	0.000294	0.000701	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	0.000293	0.000701	CbGpPWpGaD
Lithium—Dizziness—Docetaxel—skin cancer	0.000292	0.00113	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—HRAS—skin cancer	0.000289	0.00069	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—skin cancer	0.000283	0.000675	CbGpPWpGaD
Lithium—Vomiting—Docetaxel—skin cancer	0.000281	0.00108	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—IL6—skin cancer	0.000281	0.000671	CbGpPWpGaD
Lithium—Rash—Docetaxel—skin cancer	0.000279	0.00107	CcSEcCtD
Lithium—Dermatitis—Docetaxel—skin cancer	0.000278	0.00107	CcSEcCtD
Lithium—GSK3B—B Cell Activation—KRAS—skin cancer	0.000278	0.000665	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLI2—skin cancer	0.000278	0.000663	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KRAS—skin cancer	0.000277	0.000662	CbGpPWpGaD
Lithium—GSK3B—Insulin Signaling—HRAS—skin cancer	0.000277	0.000662	CbGpPWpGaD
Lithium—Headache—Docetaxel—skin cancer	0.000277	0.00107	CcSEcCtD
Lithium—GSK3B—Developmental Biology—CDK4—skin cancer	0.000277	0.000661	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—IL6—skin cancer	0.000277	0.00066	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—HRAS—skin cancer	0.000276	0.000659	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—HRAS—skin cancer	0.000275	0.000656	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—HRAS—skin cancer	0.000273	0.000652	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—HRAS—skin cancer	0.000272	0.000649	CbGpPWpGaD
Lithium—GSK3B—Disease—SHH—skin cancer	0.00027	0.000644	CbGpPWpGaD
Lithium—GSK3B—Disease—ENO2—skin cancer	0.00027	0.000644	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	0.000268	0.00064	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	0.000267	0.000636	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MC1R—skin cancer	0.000265	0.000633	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—IL6—skin cancer	0.000264	0.000631	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—IL6—skin cancer	0.000263	0.000628	CbGpPWpGaD
Lithium—Nausea—Docetaxel—skin cancer	0.000263	0.00101	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—IL6—skin cancer	0.000261	0.000624	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—GLI1—skin cancer	0.000261	0.000624	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—IL6—skin cancer	0.00026	0.000621	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—HRAS—skin cancer	0.000256	0.000611	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—HRAS—skin cancer	0.000256	0.000611	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	0.000256	0.000611	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SHH—skin cancer	0.000255	0.00061	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RASA1—skin cancer	0.000254	0.000606	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—HRAS—skin cancer	0.000253	0.000605	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—HRAS—skin cancer	0.000251	0.0006	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—HRAS—skin cancer	0.00025	0.000597	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SUFU—skin cancer	0.000248	0.000591	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—IL6—skin cancer	0.000245	0.000585	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	0.000245	0.000585	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—skin cancer	0.000245	0.000585	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—IL6—skin cancer	0.000243	0.000579	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMO—skin cancer	0.000242	0.000578	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTCH1—skin cancer	0.000242	0.000578	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—HRAS—skin cancer	0.000242	0.000577	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—skin cancer	0.000242	0.000577	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—skin cancer	0.00024	0.000574	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—IL6—skin cancer	0.000239	0.000572	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NRAS—skin cancer	0.000238	0.000569	CbGpPWpGaD
Lithium—GSK3B—Immune System—FOXO4—skin cancer	0.000238	0.000568	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—HRAS—skin cancer	0.000237	0.000565	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—HRAS—skin cancer	0.000236	0.000563	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PTGER4—skin cancer	0.000236	0.000563	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	0.000227	0.000541	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—IL6—skin cancer	0.000226	0.000539	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—skin cancer	0.000221	0.000528	CbGpPWpGaD
Lithium—GSK3B—Disease—FOXO4—skin cancer	0.00022	0.000525	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	0.000217	0.000518	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—NRAS—skin cancer	0.000216	0.000515	CbGpPWpGaD
Lithium—GSK3A—Disease—ERCC2—skin cancer	0.000212	0.000506	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FOXO4—skin cancer	0.000208	0.000497	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KRAS—skin cancer	0.000205	0.00049	CbGpPWpGaD
Lithium—GSK3A—Disease—TERT—skin cancer	0.000199	0.000474	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—skin cancer	0.000194	0.000464	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SHH—skin cancer	0.000189	0.000451	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RASA1—skin cancer	0.000188	0.000448	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—KRAS—skin cancer	0.000186	0.000443	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—NRAS—skin cancer	0.000184	0.000439	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMO—skin cancer	0.000179	0.000427	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTCH1—skin cancer	0.000179	0.000427	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—skin cancer	0.000178	0.000425	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—NRAS—skin cancer	0.000177	0.000422	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—HRAS—skin cancer	0.000174	0.000416	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTGER4—skin cancer	0.000174	0.000416	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—skin cancer	0.000167	0.000398	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KRAS—skin cancer	0.000158	0.000378	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—HRAS—skin cancer	0.000158	0.000377	CbGpPWpGaD
Lithium—GSK3A—Disease—BRAF—skin cancer	0.000157	0.000376	CbGpPWpGaD
Lithium—GSK3B—Disease—ERCC2—skin cancer	0.000157	0.000374	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FOXO4—skin cancer	0.000154	0.000367	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NRAS—skin cancer	0.000154	0.000367	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KRAS—skin cancer	0.000152	0.000363	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—skin cancer	0.000151	0.00036	CbGpPWpGaD
Lithium—GSK3B—Disease—TERT—skin cancer	0.000147	0.000351	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TERT—skin cancer	0.000139	0.000332	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—NRAS—skin cancer	0.000136	0.000324	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—HRAS—skin cancer	0.000134	0.000321	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—KRAS—skin cancer	0.000132	0.000316	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—NRAS—skin cancer	0.00013	0.000312	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—HRAS—skin cancer	0.000129	0.000308	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—skin cancer	0.000129	0.000307	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—skin cancer	0.000127	0.000303	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KRAS—skin cancer	0.000117	0.000279	CbGpPWpGaD
Lithium—GSK3B—Disease—BRAF—skin cancer	0.000116	0.000278	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—HRAS—skin cancer	0.000113	0.000269	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KRAS—skin cancer	0.000112	0.000268	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BRAF—skin cancer	0.00011	0.000263	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—skin cancer	0.000108	0.000257	CbGpPWpGaD
Lithium—GSK3A—Immune System—NRAS—skin cancer	0.000107	0.000256	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TERT—skin cancer	0.000103	0.000245	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—HRAS—skin cancer	9.94e-05	0.000237	CbGpPWpGaD
Lithium—GSK3A—Disease—NRAS—skin cancer	9.89e-05	0.000236	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—HRAS—skin cancer	9.54e-05	0.000228	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—skin cancer	9.51e-05	0.000227	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—skin cancer	9.39e-05	0.000224	CbGpPWpGaD
Lithium—GSK3A—Immune System—KRAS—skin cancer	9.22e-05	0.00022	CbGpPWpGaD
Lithium—GSK3A—Disease—KRAS—skin cancer	8.51e-05	0.000203	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BRAF—skin cancer	8.14e-05	0.000194	CbGpPWpGaD
Lithium—GSK3B—Immune System—NRAS—skin cancer	7.91e-05	0.000189	CbGpPWpGaD
Lithium—GSK3A—Immune System—HRAS—skin cancer	7.83e-05	0.000187	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—skin cancer	7.5e-05	0.000179	CbGpPWpGaD
Lithium—GSK3B—Disease—NRAS—skin cancer	7.3e-05	0.000174	CbGpPWpGaD
Lithium—GSK3A—Disease—HRAS—skin cancer	7.23e-05	0.000173	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NRAS—skin cancer	6.92e-05	0.000165	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—skin cancer	6.92e-05	0.000165	CbGpPWpGaD
Lithium—GSK3B—Immune System—KRAS—skin cancer	6.81e-05	0.000163	CbGpPWpGaD
Lithium—GSK3B—Disease—KRAS—skin cancer	6.29e-05	0.00015	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KRAS—skin cancer	5.96e-05	0.000142	CbGpPWpGaD
Lithium—GSK3B—Immune System—HRAS—skin cancer	5.79e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—skin cancer	5.54e-05	0.000132	CbGpPWpGaD
Lithium—GSK3B—Disease—HRAS—skin cancer	5.34e-05	0.000128	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—skin cancer	5.3e-05	0.000126	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NRAS—skin cancer	5.12e-05	0.000122	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—skin cancer	5.11e-05	0.000122	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HRAS—skin cancer	5.06e-05	0.000121	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—skin cancer	4.85e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KRAS—skin cancer	4.4e-05	0.000105	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—skin cancer	3.91e-05	9.35e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HRAS—skin cancer	3.74e-05	8.94e-05	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—skin cancer	3.58e-05	8.55e-05	CbGpPWpGaD
